scholarly journals Autoantibodies against islet cell antigens in children with type 1 diabetes mellitus

Oncotarget ◽  
2018 ◽  
Vol 9 (23) ◽  
pp. 16275-16283 ◽  
Author(s):  
Bi-Wen Cheng ◽  
Fu-Sung Lo ◽  
An-Mei Wang ◽  
Chen-Mei Hung ◽  
Chi-Yu Huang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Cell ◽  
Islet Cell Antigens

scholarly journals Evaluation of Metabolic Control Using a Continuous Subcutaneous Glucose Monitoring System in Patients with Type 1 Diabetes Mellitus who Achieved Insulin Independence after Islet Cell Transplantation

2005 ◽  
Vol 14 (2-3) ◽  
pp. 77-84 ◽  
Author(s):  
Milene C. Geiger ◽  
Jacqueline V. Ferreira ◽  
Muhammad M. Hafiz ◽  
Tatiana Froud ◽  
David A. Baidal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Metabolic Control ◽  
Cell Transplantation ◽  
Monitoring System ◽  
Islet Cell ◽  
Glucose Monitoring ◽  
Islet Cell Transplantation

This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre- and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.

Immunosuppression and Procedure-Related Complications in 26 Patients with Type 1 Diabetes Mellitus Receiving Allogeneic Islet Cell Transplantation

2005 ◽  
Vol 80 (12) ◽  
pp. 1718-1728 ◽  
Author(s):  
Muhammad M. Hafiz ◽  
Raquel N. Faradji ◽  
Tatiana Froud ◽  
Antonello Pileggi ◽  
David A. Baidal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation

Anti-islet Cell Antibodies in a Sample of Egyptian Females with Gestational Diabetes and its Relation to Development of Type 1 Diabetes Mellitus

2018 ◽  
Vol 14 (4) ◽  
pp. 389-394 ◽  
Author(s):  
Hanan M. Amer ◽  
Rania S. Abd El Baky ◽  
Merhan S. Nasr ◽  
Laila M. Hendawy ◽  
Wessam A. Ibrahim ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Gestational Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Cell ◽  
Islet Cell Antibodies
Sign in / Sign up

Export Citation Format

Share Document